QIAGEN Launches the First Validated Portfolio Linking Genome-Wide RNAi and qPCR-Based Gene Expression Assays
QIAGEN N.V. announced the launch of what it believes is the world's first and largest product portfolio for integrated genome-wide RNAi and SYBR(R) Green-based RT-PCR. The offering addresses a critical need in research and drug development. QIAGEN believes that this new offering represents a substantial improvement over current offerings and that it provides access to a new dimension of value for customers in the rapidly growing field of RNAi.
Gene Silencing, or RNA interference (RNAi) uses target-specific sequences of short interfering RNA molecules (siRNA molecules) to knock-down, or "silence" targeted genes to infer their function. The success of the RNAi assay is measured through gene expression (using tools such as microarrays and quantitative PCR (qPCR) assays) as well as protein assays. RNAi and gene expression assays are therefore often used in concert and their synchronization is a key requirement and challenge for successful research.
The new offering developed by QIAGEN provides a very broad range of optimized and validated RNAi-based gene silencing solutions and, in addition, also links such RNAi solutions with the corresponding gene expression assay used in the subsequent qPCR-based knockdown validation. The features of this validated offering create a new dimension in utility and ease of use by eliminating the need for laborious and time-consuming assay development which consumes costly probe-based qRT-PCR reagents as well as eliminating the need to repeatedly design, synthesize, and test siRNA and primers.
The siRNA assay portfolio comprises two types of siRNA products from QIAGEN, the HP GenomeWide and the HP Validated siRNAs. These siRNA products were designed using the innovative HiPerformance siRNA Design Algorithm, licensed from Novartis Pharmaceuticals, a unique combination of the design algorithm with QIAGEN's proprietary sensitive homology search.
Both are highly potent and specific siRNA products which deliver guaranteed knockdown. The matching ready-to-use and validated SYBR(R) Green-based qRT-PCR assay portfolio is supplemented by QIAGEN's QuantiTect(R) Primer Assays for real-time RT-PCR providing specificity and sensitivity comparable to sequence-specific probe-based assays. The launch of this new offering allows customers to purchase proven siRNAs and RT-PCR assays for every gene of the human, mouse, and rat genomes.
Other news from the department research and development
